![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 21, 2025
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2025 Group Meeting
November 21, 2025
In an annual evaluation, 37 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 21, 2025
Compliance guidance for an updated policy that aims to accelerate free public access to research funded by the National Institutes of Health
August 28, 2025
Four tips for creating and maintaining a strong patient-oncologist relationship
February 19, 2025
Patient-reported outcomes research has led to many discoveries that have influenced current research priorities and the way the Group designs its trials
December 23, 2024
Julie Brahmer, Naomi Haas, and Jedd Wolchok offer insights into a complicated issue that pertains to biomarker testing for treatment selection
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
November 25, 2024
In an annual evaluation, 54 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
October 17, 2024
The Patient-Reported Outcomes (PRO) Advisory Group guides study investigators on how best to include PRO measures and endpoints in clinical trials
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials